[Objectives] To screen the active components and core targets of Gastrodia elata Bl. based on network pharmacology, and further explore its potential molecular mechanism in preventing and treating chronic heart failur...[Objectives] To screen the active components and core targets of Gastrodia elata Bl. based on network pharmacology, and further explore its potential molecular mechanism in preventing and treating chronic heart failure (CHF).[Methods] The candidate active constituents of G. elata Bl. were screened by HERB, ETCM (Encyclopedia of Traditional Chinese Medicine) database, and bioinformatics analysis tool BATMAN-TCM platform, Swiss Target Prediction platform was used to predict compound targets, and CHF disease targets were searched in GeneCards and OMIM databases;the intersection targets were taken, and the String database and Cytoscape 3.10.0 software were used for protein-protein interaction (PPI) and topological analysis to obtain key active constituents and core target genes;the online tool bioinformatics platform was used for gene ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of common targets. Using the active constituent of G. elata Bl. as ligand and its core target as receptor, molecular docking visualization was carried out.[Results] 136 common targets of active constituents of G. elata Bl. and CHF were screened out, which mainly involved AGE-RAGE signaling pathway, lipid and atherosclerosis, interleukin-17 signaling pathway, non-alcoholic fatty liver, diabetic cardiomyopathy, cancer and other signaling pathways. The core target proteins mainly included albumin, catalytic subunit α activated by protein kinase CAMP, insulin gene, interleukin-1β, tumor necrosis factor, estrogen receptor 1, interferon γ, etc. The results of molecular docking showed that the ligand of the compound had good affinity with the target receptor.[Conclusions] G. elata Bl. prevents and treats CHF through multiple components, multiple targets, and multiple pathways. The potential mechanism of G. elata Bl. in treating CHF was preliminarily explored, providing a certain theoretical basis for subsequent research on its pharmacological material basis in treating CHF.展开更多
文摘[Objectives] To screen the active components and core targets of Gastrodia elata Bl. based on network pharmacology, and further explore its potential molecular mechanism in preventing and treating chronic heart failure (CHF).[Methods] The candidate active constituents of G. elata Bl. were screened by HERB, ETCM (Encyclopedia of Traditional Chinese Medicine) database, and bioinformatics analysis tool BATMAN-TCM platform, Swiss Target Prediction platform was used to predict compound targets, and CHF disease targets were searched in GeneCards and OMIM databases;the intersection targets were taken, and the String database and Cytoscape 3.10.0 software were used for protein-protein interaction (PPI) and topological analysis to obtain key active constituents and core target genes;the online tool bioinformatics platform was used for gene ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of common targets. Using the active constituent of G. elata Bl. as ligand and its core target as receptor, molecular docking visualization was carried out.[Results] 136 common targets of active constituents of G. elata Bl. and CHF were screened out, which mainly involved AGE-RAGE signaling pathway, lipid and atherosclerosis, interleukin-17 signaling pathway, non-alcoholic fatty liver, diabetic cardiomyopathy, cancer and other signaling pathways. The core target proteins mainly included albumin, catalytic subunit α activated by protein kinase CAMP, insulin gene, interleukin-1β, tumor necrosis factor, estrogen receptor 1, interferon γ, etc. The results of molecular docking showed that the ligand of the compound had good affinity with the target receptor.[Conclusions] G. elata Bl. prevents and treats CHF through multiple components, multiple targets, and multiple pathways. The potential mechanism of G. elata Bl. in treating CHF was preliminarily explored, providing a certain theoretical basis for subsequent research on its pharmacological material basis in treating CHF.
